Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan.

DiBonaventura MD, Shah-Manek B, Higginbottom K, Penrod JR, Yuan Y.

Ther Clin Risk Manag. 2019 Feb 28;15:355-366. doi: 10.2147/TCRM.S183216. eCollection 2019.

2.

Animal behavior case of the month. Underlying anxiety disorder in an aggressive dog.

Day C, Higginbottom KB.

J Am Vet Med Assoc. 2013 Apr 15;242(8):1071-3. doi: 10.2460/javma.242.8.1071. No abstract available.

PMID:
23547668
3.

Cell death in leukemia: passenger protein regulation by topoisomerase inhibitors.

Jahnke U, Higginbottom K, Newland AC, Cotter FE, Allen PD.

Biochem Biophys Res Commun. 2007 Oct 5;361(4):928-33. Epub 2007 Jul 30.

PMID:
17681274
5.

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.

Cancer Res. 2007 Mar 15;67(6):2783-90.

6.

XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.

Cummings M, Higginbottom K, McGurk CJ, Wong OG, Köberle B, Oliver RT, Masters JR.

Biochem Pharmacol. 2006 Jul 14;72(2):166-75. Epub 2006 May 4.

PMID:
16756962
7.
8.

Etoposide-mediated deregulation of the G2M checkpoint in myeloid leukaemic cell lines results in loss of cell survival.

Higginbottom K, Cummings M, Newland AC, Allen PD.

Br J Haematol. 2002 Dec;119(4):956-64.

PMID:
12472573
9.

p53-mediated downregulation of Chk1 abrogates the DNA damage-induced G2M checkpoint in K562 cells, resulting in increased apoptosis.

Cummings M, Siitonen T, Higginbottom K, Newland AC, Allen PD.

Br J Haematol. 2002 Feb;116(2):421-8.

PMID:
11841447

Supplemental Content

Loading ...
Support Center